DOCSLIB.ORG

Transfer and Metabolism of Retinol by the Perfused Human Placenta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transfer and Metabolism of Retinol by the Perfused Human Placenta 0031-3998/92/3202-0195$03.00/0 PEDIATRIC RESEARCH Vol. 32, No.2, 1992 Copyright © 1992 International Pediatric Research Foundation, Inc. Printed in U.S.A. Transfer and Metabolism of Retinol by the Perfused Human Placenta JOSEPH DANCIS, MORTIMER LEVITZ, JOSEPH KATZ, DAVID WILSON, WILLIAM S. BLANER, ROSEANN PIANTEDOSI, AND DEWITT S. GOODMAN' Department ofPediatrics [J.D., D.Wj and Department ofObstetrics and Gynecology [M.L., J.K.j, New York University Medical Center and the Institute ofHuman Nutrition, Columbia University College ofPhysicians and Surgeons [WS.B., R.P., D.S.G.j, New York, New York 10016 ABSTRACf. The transfer and metabolism of retinol by The importance of vitamin A to the developing mammalian human placenta was investigated using an in vitro perfusion fetus has been amply demonstrated in the experimental animal. system with independent maternal and fetal circulations. Both deficiencies and excesses are teratogenic (1, 2). The perti­ 3H-retinol bound to albumin added to the maternal perfus­ nence of these observations to the human has recently become ate was rapidly taken up and concentrated by the placenta tragically evident. Retinoic acid administered to the pregnant to levels 16.5 ± 5.28 times the maternal perfusate. Ap­ female for the treatment of acne has caused severe congenital proximately 8% of the retinol retained in the placenta was abnormalities in the newborn infant (3). esterified. No metabolites were detected in the perfusates. Despite its obvious importance, little is known about the Perfusion of placenta with retinol bound to retinol-binding placental transfer of retinoids. The question has been approached protein (RBP) reduced the placental concentration to 4.4 in the sheep (4) and monkey (5), but the placental role is difficult ± 1.72 times the maternal concentration and eliminated to deduce from studies in the intact animal and extrapolation of evidence of metabolism. The transfer rate of RBP:3H­ results to the human is uncertain. Measurements have been retinol was less than that of albumin.'r'Ccretinol when made in the human of maternal and cord retinol levels (6) that measured concurrently in three experiments (clearances are interesting but shed little light on placental functions. Torma 0.11 versus 0.75 mL/min, 0.21 versus 1.7 mL/min, and 0.29 and Vahlquist (7) have studied the uptake of vitamin A and RBP versus 0.48 mL/min, respectively). Transfer of the radio­ by fragments of human placenta in vitro and speculated concern­ active retinol was more rapid than 125I_RBP or albumin, ing the transplacental process. The model, however, does not indicating that retinol was transferred independently of the permit differentiation of events at the maternal surface of the proteins. The transfer index of retinol (clearance reti­ placenta from those at the fetal surface. nol:clearance L-glucose) was 0.73 ± 0.085 compared to 2.1 In the present study, we have used the technique of in vitro ± 0.36 for thiamin and 3.4 ± 0.95 for riboflavin, both perfusion of a human placental lobule. By establishing independ­ water-soluble vitamins with active transport systems. The ent "maternal" and "fetal" circulations, it was possible to study retinol transferred to the fetal perfusate is not bound to the transplacental transfer of retinol, the principal circulating RBP, as demonstrated by gel filtration chromatography form of vitamin A. In vitro, retinol circulates bound to a specific and chromatography on a transthyretin affinity column, serum protein, RBP, which in turn complexes with TTR (8, 9). despite the availability of RBP in the cord serum added to We have investigated the placental transfer and metabolism of the perfusate. The endogenous retinol in the cord serum is retinol bound to RBP and compared the results to retinol bound bound to RBP. The conclusions derived are that RBP nonspecifically to serum albumin. The comparison has provided binding reduces the accumulation of retinol in the placenta insights into the physiologic role of RBP and the biochemical and the transfer to the fetus, that retinol is transferred mechanism through which retinol is taken up by the tissues. intact to the fetal circulation where immediate binding is not to RBP, and that redistribution to RBP occurs subse­ MATERIALS AND METHODS quently, possibly in fetal liver. (Pediatr Res 32: 195-199, 1992) Perfusion technique. Term placentas of clinically normal preg­ nancies were obtained after delivery by cesarean section or by vagina. Independent maternal and fetal circulations were estab­ Abbreviations lished to a placental lobule as previously described (10). Flow RBP, retinol-binding protein rates approximated 12-15 mL/min on the maternal side and 4­ TIR, transthyretin 6 mL/min on the fetal side. In the "closed" experiments, the RBP:retinol, retinol bound to retinol-binding protein perfusate was recirculated through a 70-mL reservoir. The per­ albumin:retinol, retinol bound to albumin fusions were performed under reduced lighting, as were all pro­ TCA, trichloroacetic acid cedures with retinol, because of its light sensitivity. Perfusate. The basic perfusate consisted of Earle's buffered salt solution equilibrated against Oz-COz, 95-5%, pH 7.4, with 150 mg/dl. of n-glucose and mixed amino acids in physiologic con­ centration. In the experiments with albumin-bound retinol, 10 g/L BSA was added to the perfusate with 3H-retinol -20000 cpm/ml, and retinol 1.7 JLmol/L. Ten g/L albumin in the Received January 2, 1992; accepted March 20, 1992. perfusate solubi1izes the retinol and provides sufficient binding Correspondence and reprint requests: Joseph Dancis, M.D., New York Univer­ to prevent absorption to the perfusion tubing and apparatus sity Medical Center, 550 First Ave., TH 528, New York, NY 10016. Supported by grants from the Langer Foundation and the NIH (DK05968, similar to previous experience with vitamin D (11). Binding was DK43097). accomplished by incubating 3H-retinol with BSA for 1 h. For the 'Deceased. RBP experiments, 3H-retinol was bound to RBP by incubation 195 196 DANCIS E T AL. at 3rC .for 1 h or at 5°C overnight, while rotating gently. The RESULTS RBP:retmol was added to perfusate containing 20% maternal serum. Transfer and Metabolism ofAlbumin-Bound Retinol. 3H-reti­ nol was incubated with serum albumin at 3rC for 1 h which Preparation of samples for analysis. Perfusate samples were add ed directly to scintillant to determine radioactivity. If there as demonstrated by TCA p;ecipita­ was an insufficient concentration ofcounts for chromatographic tion. The albumin-bound retinol was added to the maternal perfusate, which contained 10 g/L serum albumin and recircu­ an alysis, samples were first concentrated with an Amicon-BI5 concentrator (Amicon Corp., Beverly, MA) for gel filtration lated for duration ofthe perfusion. The fetal pe;fusate, which analysis or by extraction with hexane for reverse phase chro ma­ also IO .g/L serum albumin, was kept open (two tography. Th.roughout the analytical procedures, retinol was expenments) or recirculated (four experiments). protected against oxidation by the addition ofbutylated hydrox­ Placental uptake. Uptake of 3H-retinol from the maternal ytoluene, 6.1 mM (1 mg/ml.), or a-tocopherol, 100 JLg. perfusate was very rapid during the first 20 min and continued At the end of the perfusion, 2-4 g of villous tissue was dissected at a slower rate throughout the perfusion. At the end of the from the perfused placenta and homogenized in 10 volumes of perfusion , the concentrations of 3H-retinol in the placenta and methanol:hexane (1:9). The extraction was repeated and both m the maternal perfusate were measured. The concentration in extracts combined and evaporated under vacuum. The residue the placenta was 16.5 ± 5.28 times that in the perfusate (Table was dissolved in 3 mL hexane containing 6.1 mM butylated 1). hydroxytoluene, transferred to a small tube, and taken to dryness . In five experiments, the albumin-bound 3H-retinol was added The residue was dissolved in 0.5-1 .0 mL of meth anol and passed to the fetal perfusate that was recirculated. The ratio of the through a 0.22-JLm filter, and 100 to 500 JLL were analyzed by concentrations of 3H-retinol in the placenta to the fetal perfusate HPLC. was 16.0 ± 4.79, suggesting that similar mechanisms were in­ Chromatographic analysis. Reverse phase HPLC was used to volved in uptake and concentration of retinol from the maternal identify retinoic acid, retinol, and the retinyl esters. Separation and fetal perfusate. was on a Waters RPC-I8 column (Waters Associates Milford Metabolism. The maternal and fetal perfusates were analyzed MA) with a UV detector at 325 nm . The mobile was 80% by reverse phase HPLC. No radioacti ve metabolites were de­ acetonitrile in 1% ammonium acetate with a flow rate of 1 mLI tected. In four experiments, the placenta was extracted at the min. Retinol and retinoic acid, 100 JLg, were added to the sample completion of the perfusion and also analyzed. Over 90% of the be,fore injection to serve as standards, the former eluting at 7 radioactivity coeluted with retinol ; 8, 4, 7, and 11% eluted with retinyl esters. Retinoic acid was not detected. nun and the latter at 4.5 min . For the retinyl esters, 100% 3H-retinol methanol was the mobile phase, retinyl palmitate was the stand­ Placental transfer. Transplacental clearances of were ard, and elution time was 13.4 min (12). calculated (Table 2). 14C-inulin was included in these experiments High performance gel filtration was performed to separate to provide a simultaneous ofdiffusion ofa large (5-kD), according to molecular size (13). Samples were injected water-soluble molecule. Retinol was transferred IO-fold more into a Waters TSK 2000 SW column equipped with a UV or rapidly than inulin (10.2 ± 2.58).
Load more

Recommended publications
  • Alpha1-Antitrypsin, a Reliable Endogenous Marker for Intestinal Protein Loss and Its Application in Patients with Crohn's Disease
    Gut: first published as 10.1136/gut.24.8.718 on 1 August 1983. Downloaded from Gut, 1983, 24, 718-723 Alpha1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease U KARBACH, K EWE, AND H BODENSTEIN From the I. Medizinische Klinik und Poliklinik, Mainz, FR Germany. SUMMARY Intestinal protein loss is generally determined by radio-labelled macromolecules. Alpha1-antitrypsin has been proposed as an endogenous marker for protein losing enteropathy, but different opinions exist about its reliability. In 25 patients with Crohn's disease faecal protein loss was studied with intestinal alpha1-antitrypsin (x1AT) clearance. Simultaneously, in 10 patients x1AT clearance was compared with faecal 51Cr clearance after intravenous 51Cr-albumin injection. There was a linear relation (p<0O05) between X1AT clearance and 51Cr clearance in these cases. In all patients ox1AT clearance was raised above control values. &1AT clearance, however, did not correlate with the activity index of Crohn's disease.1 This index does not contain direct critieria of intestinal inflammation, does not take into account localisation or extent of inflammation, and includes complications such as extraintestinal manifestations, fistuli, stenoses not necessarily related to actual mucosal involvement. It is concluded that x1AT is a reliable marker for intestinal protein loss and that the intestinal changes of Crohn's disease generally lead to an increased protein exudation into the gut. http://gut.bmj.com/ Gastrointestinal loss of plasma proteins can be clearance with the conventional 5 Cr-albumin detected by a variety of labelled macromolecules: method. According to Keaney and Kelleherl° the 59Fe-labelled dextran and 131I_PVP3 are not split by contradictory results could be caused by a difference digestive enzymes; the radioactive isotopes 51Cr- in methods and by comparison of different albumin,4 67Cu-ceruloplasmins or 95Nb-albumin6 are parameters.
    [Show full text]
  • Albumin (Human) 25% Solution, Usp
    PRODUCT MONOGRAPH ALBUMIN (HUMAN) 25% SOLUTION, USP Albumin (Human) 25%, USP Intravenous Solution, 25% Manufacturer’s Standard Plasma Substitute/Blood Derivative Manufactured by: Imported and Distributed by: Date of Approval: Grifols Therapeutics Inc. Grifols Canada Ltd. December 19, 2011 8368 U.S. 70 Bus. Hwy West 5060 Spectrum Way, Clayton, North Carolina Suite 405 27520 Mississauga, Ontario U.S.A. L4W 5N5 Prepared for: Canadian Blood Services Ottawa, Ontario K1G 4J5 Prepared for: Héma-Québec Saint-Laurent, Québec H4R 2W7 Submission Control No: 152126 Page 1 of 19 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 DESCRIPTION....................................................................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................6 WARNINGS AND PRECAUTIONS..................................................................................6 ADVERSE REACTIONS....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION................................................................................8
    [Show full text]
  • Sex Hormone-Binding Globulin (SHBG) As an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome
    International Journal of Molecular Sciences Review Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome Xianqin Qu 1,* and Richard Donnelly 2 1 School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia 2 School of Medicine, University of Nottingham, Derby DE22 3DT, UK; [email protected] * Correspondence: [email protected]; Tel.: +61-2-95147852 Received: 1 October 2020; Accepted: 28 October 2020; Published: 1 November 2020 Abstract: Human sex hormone-binding globulin (SHBG) is a glycoprotein produced by the liver that binds sex steroids with high affinity and specificity. Clinical observations and reports in the literature have suggested a negative correlation between circulating SHBG levels and markers of non-alcoholic fatty liver disease (NAFLD) and insulin resistance. Decreased SHBG levels increase the bioavailability of androgens, which in turn leads to progression of ovarian pathology, anovulation and the phenotypic characteristics of polycystic ovarian syndrome (PCOS). This review will use a case report to illustrate the inter-relationships between SHBG, NAFLD and PCOS. In particular, we will review the evidence that low hepatic SHBG production may be a key step in the pathogenesis of PCOS. Furthermore, there is emerging evidence that serum SHBG levels may be useful as a diagnostic biomarker and therapeutic target for managing women with PCOS. Keywords: adolescents; hepatic lipogenesis; human sex hormone-binding globulin; insulin resistance; non-alcoholic fatty liver disease; polycystic ovary syndrome 1. Introduction Polycystic ovary syndrome (PCOS) is a complex, common reproductive and endocrine disorder affecting up to 10% of reproductive-aged women [1].
    [Show full text]
  • Serum Albumin
    Entry Serum Albumin Daria A. Belinskaia 1,*, Polina A. Voronina 1, Anastasia A. Batalova 1 and Nikolay V. Goncharov 1,2 1 Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, pr. Torez 44, 194223 St. Petersburg, Russia; [email protected] (P.A.V.); [email protected] (A.A.B.); [email protected] (N.V.G.) 2 Research Institute of Hygiene, Occupational Pathology and Human Ecology, p/o Kuzmolovsky, 188663 Leningrad Region, Russia * Correspondence: [email protected] Definition: Being one of the most abundant proteins in human and other mammals, albumin plays a crucial role in transporting various endogenous and exogenous molecules and maintaining of colloid osmotic pressure of the blood. It is not only the passive but also the active participant of the pharmacokinetic and toxicokinetic processes possessing a number of enzymatic activities. A free thiol group of the albumin molecule determines the participation of the protein in redox reactions. Its activity is not limited to interaction with other molecules entering the blood: of great physiological importance is its interaction with the cells of blood, blood vessels and also outside the vascular bed. This entry contains data on the enzymatic, inflammatory and antioxidant properties of serum albumin. Keywords: albumin; blood plasma; enzymatic activities; oxidative stress 1. Introduction: Physico-Chemical, Evolutionary and Genetic Aspects Albumin is a family of globular proteins, the most common of which are the serum albumins. All the proteins of the albumin family are water-soluble and moderately soluble Citation: Belinskaia, D.A.; Voronina, in concentrated salt solutions. The key qualities of albumin are those of an acidic, highly P.A.; Batalova, A.A.; Goncharov, N.V.
    [Show full text]
  • Monoclonal Anti-Albumin Antibody Produced in Mouse (A2672
    MONOCLONAL ANTI-HUMAN SERUM ALBUMIN CLONE HSA-9 Mouse Ascites Fluid Product No. A 2672 Monoclonal anti-Human Serum Albumin (mouse IgG1 albumin levels may indicate disease states such as isotype) is derived from the hybridoma produced by the malnutrition, cirrhosis, nephrotic syndrome, diabetes, fusion of mouse myeloma cells and splenocytes from an gastrointestinal and hepatic diseases, thermal burns and immunized mouse. A releasate of human platelets was pulmonary disease. used as the immunogen. The isotype is determined by a double diffusion assay using immunoglobulin and Reagents subclass specific antisera. The product is provided as ascites fluid with 0.1% sodium azide as a preservative. Monoclonal anti-Human Serum Albumin is specific for human serum albumin and shows cross reactivity with Precautions rhesus monkey and baboon albumins when tested in an Due to the sodium azide content a material safety data immunoblot procedure under non-reducing conditions. sheet (MSDS) for this product has been sent to the The product detects an epitope present under attention of the safety officer of your institution. Consult non-reducing conditions. The antibody shows no cross the MSDS for information regarding hazards and safe reactivity with serum albumin from bovine, cat, catfish, handling practices. chicken, dog, donkey, gibbon, goat, guinea pig, hamster, horse, marmoset, mouse, pig, pigeon, rabbit, rat, sheep Product Profile or turkey. A minimum dilution of 1:500 was determined by ELISA using human serum albumin at 50mg/ml as the coating Monoclonal anti-Human Serum Albumin may be used for solution. the determination of albumin in human body fluids by ELISA. The antibody may be used in immunoblotting In order to obtain best results it is recommended that under non-reducing conditions.
    [Show full text]
  • (HCII) Heparin Cofactor II Antigen
    Supplied Materials: 1.1.1. Capture Antibody (HCII(HCII----EIAEIAEIAEIA----C):C):C):C): One yellow-capped vial ** REPRESENTATIVE DATA SHEETS** containing 0.4 ml of polyclonal affinity purified anti-HCII antibody for coating plates. MatchedMatchedMatched-Matched---PairPair Antibody Set 2.2.2. Detecting Antibody (HCII(HCII----EIAEIAEIAEIA----D):D):D):D): Four neutral-capped for ELISA of human tubes each containing 10 ml of pre-diluted peroxidase conjugated polyclonal anti-HCII antibody for detection of Heparin Cofactor II antigen (HCII) captured HCII. °°° Sufficient reagent for 4 x 96 wellwell4 plates Store reagents at 22----8888 CCC Product #: HCII-HCII-EIAEIA Product #:Product #: HCIIHCII-- EIAEIA Materials Required but not Provided: Lot # SAMPLE Expiry Date:Expiry Date: SAMPLE 1. Coating Buffer: 50 mM Carbonate 1.59g of Na2CO3 and 2.93g of NaHCO3 up to 1 litre. Adjust pH to 9.6. Store at 2-8°C up to 1 month. 222. PBS: (base for wash buffer and blocking buffer) PBS:PBS: 8.0g NaCl, 1.15g Na2HPO4, 0.2g KH2PO4 and 0.2g KCl, up to Store atStore at 2 2----8888°°°CCC 1 litre. Adjust pH to 7.4, if necessary. Store up to 1 month at 2-8°C, discard if there is evidence of microbial growth. For Research Use Only Not for use in diagnostic procedures. 333. Wash Buffer: PBS-Tween (0.1%,v/v) To 1 litre of PBS add 1.0 ml of Tween-20. Check that the pH is 7.4. Store at 2-8°C up to 1 week. Description of Heparin Cofactor II (HCII) Heparin Cofactor II (HCII), also known as heparin cofactor A 4.
    [Show full text]
  • Understanding Your Lab Results: Comprehensive Metabolic Screening Panel
    Understanding Your Lab Results: Comprehensive Metabolic Screening Panel CHOLESTEROL and TRIGLYCERIDES are fats necessary for normal cell function. However, elevated levels of these fats have been associated with an increased risk of developing coronary disease, arteriosclerosis, and heart attack. A patient’s dietary status, medications, presence of illness, lifestyle, and family history may represent factors influencing cholesterol levels. The signifi- cance of cholesterol levels should be determined within the context of each individual patient. If your cholesterol level is 200 mg/dl or greater, please consult your physician. Triglyceride levels greater than 150 mg/dl, in a true fasting specimen, are considered elevated. In this case, please consult your physician. HDL (High-Density Lipoprotein) CHOLESTEROL, commonly known as the “GOOD” cholesterol, picks up cholesterol and transports it for removal from the body. The higher the HDL value, the lower the risk of developing coronary disease, arterioscle- rosis, and heart attack. LDL (Low-Density Lipoprotein) CHOLESTEROL, commonly known as the “BAD” cholesterol, picks up cholesterol and transports it to the cells of the body for storage. Desirable LDL levels are less than 130 mg/dl. The higher the LDL value, the greater the risk of developing coronary disease, arteriosclerosis, and heart attack. CHOLESTEROL/HDL RATIO is a calculation used to predict an increased or decreased risk of cardiovascular disease relative to a normal. The higher the ratio, the greater the risk of developing coronary disease, arteriosclerosis, and heart attack. GLUCOSE, commonly called a blood sugar, is the transport form of carbohydrates in the body as they move to storage or to utiliza- tion.
    [Show full text]
  • Albumin (Human) 25%, USP Plasbuminw-25
    3056465 (Rev. 8/2020) Albumin (Human) 25%, USP Plasbuminw-25 DESCRIPTION Albumin (Human) 25%, USP (Plasbumin®-25) is made from large pools of human venous plasma by the Cohn cold ethanol fractionation process. Part of the fractionation may be performed by another licensed manufacturer. It is prepared in accordance with the applicable requirements established by the U.S. Food and Drug Administration. Plasbumin-25 is a 25% sterile solution of albumin in an aqueous diluent. The preparation is stabilized with 0.02 M sodium caprylate and 0.02 M acetyltryptophan. The aluminum content of the product is not more than 200 µg/L. The approximate sodium content of the product is 145 mEq/L. Plasbumin-25 is clear, slightly viscous, almost colorless to yellow, amber or green. It contains no preservative. Plasbumin-25 must be administered intravenously. 3056465 Each vial of Plasbumin-25 is heat-treated at 60° C for 10 hours against the possibility of transmitting the hepatitis viruses. Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the variant Creutzfeldt-Jakob disease (vCJD) and Creutzfeldt-Jakob disease (CJD) agents.(11-14) The production steps from Pooled Plasma to Effluent IV-1 in the Plasbumin-25 manufacturing process have been shown to decrease TSE infectivity of that experimental model agent (a total of Ն7.0 logs). These studies provide reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting material, would be removed. CLINICAL PHARMACOLOGY Each 20 mL vial of Plasbumin-25 supplies the oncotic equivalent of approximately 100 mL citrated plasma; 50 mL supplies the oncotic equivalent of approximately 250 mL citrated plasma.
    [Show full text]
  • Total Protein, Albumin and Globulin Levels Following
    GLOBAL JOURNAL OF PURE AND APPLIED SCIENCES VOL. 18, NO. 1&2, 2012: 25-29 25 COPYRIGHT© BACHUDO SCIENCE CO. LTD PRINTED IN NIGERIA ISSN 1118-0579 www.globaljournalseries.com, Email: [email protected] TOTAL PROTEIN, ALBUMIN AND GLOBULIN LEVELS FOLLOWING THE ADMINISTRATION OF ACTIVITY DIRECTED FRACTIONS OF VERNONIA AMYGDALINA DURING ACETAMINOPHEN INDUCED HEPATOTOXICITY IN WISTAR ALBINO RATS V. S. EKAM AND E. O. UDOSEN (Received 24 February 2011; Revision Accepted 3 February 2012) ABSTRACT The effect of treatment with activity directed fractions of Vernonia amygdalina during acetaminophen - induced hepatotoxicity in wistar albino rats for 14 days was investigated. The 48 wistar albino rats used were divided into 8 groups of 6 rats each. Group 1 served as the normal control group and received only distilled water. Group 2 served as paracetamol control group and received only paracetamol. Groups 3-8 were treated with acetaminophen and activity directed fractions of Vernonia amygdalina. The extracts were obtained by fractionation of the crude ethanolic extract using organic solvents of increasing polarities. Paracetamol was administered at a dose of 171.41mg/kg and the fractions of vernonia amygdalina at 200mg/kg. At the end of the treatment with fractions of benzene, chloroform, ethyl acetate, butanol, methanol and residue E produced varying results in the level of total protein, albumin and globulin. Results obtained shows a significant decrease (P<0.05) in total protein level (g/dl) in the paracetamol group (23.66±0.59) compared to the normal control group (45.00±1.73). The result also shows a significant increase(P<0.05) in total protein (g/dl) in all group treated with the various fractions of vernonia amygdalina compared to the paracetamol group, with the group treated with residue E fraction having the highest protein level (g/dl) among all treatment groups (36.50±2.21).
    [Show full text]
  • Serum & Urine Protein Electrophoresis
    Serum & urine protein electrophoresis Take a test Normal or abnormal? Definitions Electrophoresis is a method of separating proteins based on their physical properties. Serum is placed on a specific medium, and a charge is applied. The net charge (positive or negative) and the size and shape of the protein commonly are used in differentiating various serum proteins. Definitions Several subsets of serum protein electrophoresis are available. The proteins are stained, and their densities are calculated electronically to provide graphical data on the absolute and relative amounts of the various proteins. Further separation of protein subtypes is achieved by staining with an immunologically active agent, which results in immunofluorescence and immunofixation. Components of Serum Protein Electrophoresis The pattern of serum protein electrophoresis results depends on the fractions of two major types of protein: albumin and globulins. Components of Serum Protein Electrophoresis Albumin, the major protein component of serum, is produced by the liver under normal physiologic conditions. Globulins comprise a much smaller fraction of the total serum protein content. The subsets of these proteins and their relative quantity are the primary focus of the interpretation of serum protein electrophoresis. Components of Serum Protein Electrophoresis Albumin, the largest peak, lies closest to the positive electrode. The next five components (globulins) are labeled alpha1, alpha2, beta1, beta2, and gamma. The peaks for these components lie toward the negative electrode, with the gamma peak being closest to that electrode. serum protein electrophoresis normal pattern ALBUMIN The albumin band represents the largest protein component of human serum. The albumin level is decreased under circumstances in which there is less production of the protein by the liver or in which there is increased loss or degradation of this protein.
    [Show full text]
  • Urinary Albumin, Transferrin and Iron Excretion in Diabetic Patients
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 40 (1991), pp. 923—926 Urinary albumin, transferrin and iron excretion in diabetic patients RANDY L. HOWARD, BRUCE BUDDINGTON, and ALLEN C. ALFREY Department of Medicine, Renal Division, University of Colorado Medical School and Veterans Administration Medical Center, Denver, Colorado, USA Urinary albumin, transferrin and iron excretion in diabetic patients. transporting protein a glomerular leak for transferrin would also The present study was undertaken to determine urinary and serum iron, increase tubule fluid and urinary iron. This could result in transferrin and albumin levels in diabetic patients with varying amounts of proteinuria. A highly significant correlation was found betweenincreased urinary iron excretion early during the course of urinary albumin and transferrin excretion over a wide range of urinary diabetic renal disease. Urinary iron excretion has only been albumin excretion (0.005 to 18 g/g creatinine) (r =0.972).The urine! rarely studied in proteinuric states, and all of these studies have serum ratio of transferrin and albumin were identical, documenting a been directed at renal diseases associated with massive protein- similar glomerular leak and tubule handling for these two proteins. In contrast to the above correlation between transferrin and albumin, uria [8—121. there was no correlation between iron and either of these proteins until Depending on the state in which iron exists in the urine it nephrotic range proteinuria had occurred, and even at that time thecould have the potential to catalyze the Haber-Weiss reaction correlation was much weaker than that found between the proteins (r = with the formation of free hydroxyl radicals [13].
    [Show full text]
  • Serum Albumin and Transferrin in Protein-Energy Malnutrition Their Use in the Assessment of Marginal Undernutrition and the Prognosis of Severe Undernutrition
    Downloaded from https://doi.org/10.1017/S0007114500020249 Br. J. Nutr. (1976), 36, 255 255 https://www.cambridge.org/core Serum albumin and transferrin in protein-energy malnutrition Their use in the assessment of marginal undernutrition and the prognosis of severe undernutrition . IP address: BY P. J. REEDS Institute of Child Health, University College Hospital, Ibadan, Nigeria, and 170.106.202.226 Department of Biochemistry, University of Surrey, Guildford, Surrey AND A. A. O. LADITAN Institute of Child Health, University College Hospital, Ibadan, Nigeria , on 25 Sep 2021 at 06:39:12 {Received 28 November 1975 - Accepted 9 January 1976) 1. Deficits in weight- and length-for-age, and serum albumin and transferrin concentrations were determined for children who were either marginally undernourished (twenty-five children) or suffering from either marasmus (thirty-two children) or kwashiorkor (twenty-six children) defined according to the Wellcome Classification (Waterlow, 1972). The measurements were also made in eight children with kwashiorkor after the loss of oedema, and in sixteen children , subject to the Cambridge Core terms of use, available at who were recovering from either marasmus or kwashiorkor. 2. The mean concentration of serum albumin was similar for children from the 'under­ nourished ' group and from the group with marasmus, but was significantly reduced in those with kwashiorkor. 3. The concentration of serum transferrin was significantly reduced in both the group of children with marasmus and those with kwashiorkor. The serum transferrin concentration was significantly lower in children with kwashiorkor when compared with the level in those with marasmus. 4. Seventeen children (seven with kwashiorkor and ten with marasmus) died.
    [Show full text]